BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsiang JC, Gane EJ, Bai WW, Gerred SJ. Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients. J Gastroenterol Hepatol. 2015;30:591-599. [PMID: 25250942 DOI: 10.1111/jgh.12790] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee WG, Wells CI, Mccall JL, Murphy R, Plank LD. Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis. Diabetes Metab Res Rev 2019;35. [DOI: 10.1002/dmrr.3157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
2 Liang W, Zhang D, Kang J, Meng X, Yang J, Yang L, Xue N, Gao Q, Han S, Gou X. Protective effects of rutin on liver injury in type 2 diabetic db/db mice. Biomed Pharmacother 2018;107:721-8. [PMID: 30138894 DOI: 10.1016/j.biopha.2018.08.046] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
3 Shen Y, Zhang J, Cai H, Shao JG, Zhang YY, Liu YM, Qin G, Qin Y. Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls. BMC Gastroenterol. 2015;15:32. [PMID: 25887997 DOI: 10.1186/s12876-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang H, Li H, Lan X, Liu F, Li B, Wei Y. Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis. Medicine (Baltimore) 2021;100:e24354. [PMID: 33530229 DOI: 10.1097/MD.0000000000024354] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kim AJ, Lim HJ, Ro H, Jung JY, Lee HH, Chung W, Chang JH. Liver cirrhosis leads to poorer survival in patients with end-stage renal disease. Korean J Intern Med. 2016;31:730-738. [PMID: 27017394 DOI: 10.3904/kjim.2014.328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, Lai CL, Yuen MF. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071-1079. [PMID: 27659292 DOI: 10.1111/apt.13804] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
7 Goh GB, Pan A, Chow WC, Yuan JM, Koh WP. Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study. Liver Int. 2017;37:251-258. [PMID: 27566448 DOI: 10.1111/liv.13241] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Sufyan M, Ali Ashfaq U, Ahmad S, Noor F, Hamzah Saleem M, Farhan Aslam M, El-Serehy HA, Aslam S. Identifying key genes and screening therapeutic agents associated with diabetes mellitus and HCV-related hepatocellular carcinoma by bioinformatics analysis. Saudi J Biol Sci 2021;28:5518-25. [PMID: 34588861 DOI: 10.1016/j.sjbs.2021.07.068] [Reference Citation Analysis]
9 Yang SC, Hsu CN, Liang CM, Tai WC, Wu CK, Shih CW, Ku MK, Yuan LT, Wang JW, Tseng KL, Hung TH, Nguang SH, Hsu PI, Wu DC, Chuah SK. Risk of Rebleeding and Mortality in Cirrhotic Patients with Peptic Ulcer Bleeding: A 12-Year Nationwide Cohort Study. PLoS One 2017;12:e0168918. [PMID: 28081567 DOI: 10.1371/journal.pone.0168918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:493-507. [PMID: 33305479 DOI: 10.1111/jvh.13452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bi Y, Yin B, Fan G. Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis. Hereditas 2021;158:14. [PMID: 33865459 DOI: 10.1186/s41065-021-00177-x] [Reference Citation Analysis]
12 Ko BJ, Kim YS, Kim SG, Park JH, Lee SH, Jeong SW, Jang JY, Kim HS, Kim BS, Kim SM. Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease. Gut Liver. 2016;10:818-825. [PMID: 27114415 DOI: 10.5009/gnl15331] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
13 Shen Y, Zhang S, Wang X, Wang Y, Zhang J, Qin G, Li W, Ding K, Zhang L, Liang F. Comparison of type 2 diabetes mellitus incidence in different phases of hepatitis B virus infection: A meta-analysis. Liver Int 2017;37:1451-60. [PMID: 27753241 DOI: 10.1111/liv.13275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
15 García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Villarreal-Pérez JZ, Maldonado-Garza HJ. Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Dig Dis Sci. 2016;61:371-380. [PMID: 26462490 DOI: 10.1007/s10620-015-3907-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
16 Li X, Wang X, Gao P. Diabetes Mellitus and Risk of Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:5202684. [PMID: 29379799 DOI: 10.1155/2017/5202684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
17 Cheng PN, Chiu YC, Chiu HC, Chien SC. The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program. Medicine (Baltimore) 2016;95:e3193. [PMID: 27015215 DOI: 10.1097/MD.0000000000003193] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
18 Arvind A, Memel ZN, Philpotts LL, Zheng H, Corey KE, Simon TG. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis. Metabolism 2021;120:154780. [PMID: 33891949 DOI: 10.1016/j.metabol.2021.154780] [Reference Citation Analysis]
19 Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, Cheung RC, Nguyen MH. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1100-9. [PMID: 34469587 DOI: 10.1111/apt.16595] [Reference Citation Analysis]
20 Liu X, Xu H, Zhan M, Niu J. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis. Med Sci Monit 2019;25:6174-80. [PMID: 31420961 DOI: 10.12659/MSM.916107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Younossi Z, Kochems K, de Ridder M, Curran D, Bunge EM, de Moerlooze L. Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. Hum Vaccin Immunother 2017;13:2695-706. [PMID: 28742983 DOI: 10.1080/21645515.2017.1353850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
22 Seto WK. Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies. World J Gastroenterol 2019; 25(3): 282-286 [PMID: 30686897 DOI: 10.3748/wjg.v25.i3.282] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
23 Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol. 2015;63:1190-1197. [PMID: 26208777 DOI: 10.1016/j.jhep.2015.07.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
24 Han H, Deng H, Han T, Zhao H, Hou F, Qi X. Association Between Hepatocellular Carcinoma and Type 2 Diabetes Mellitus in Chinese Hepatitis B Virus Cirrhosis Patients: A Case-Control Study. Med Sci Monit 2017;23:3324-34. [PMID: 28689209 DOI: 10.12659/msm.902440] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
25 Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology 2021;73:2238-50. [PMID: 32978796 DOI: 10.1002/hep.31576] [Reference Citation Analysis]
26 Zhu Y, Su Y, Zhang J, Zhang Y, Li Y, Han Y, Dong X, Li W, Li W. Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy. Mol Med Rep 2021;23:437. [PMID: 33846768 DOI: 10.3892/mmr.2021.12076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ahn SB, Powell EE, Russell A, Hartel G, Irvine KM, Moser C, Valery PC. Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. Hepatol Commun. 2020;4:1279-1292. [PMID: 32923832 DOI: 10.1002/hep4.1536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chan AWH, Wong GLH, Chan H, Tong JHM, Yu Y, Choi PCL, Chan HLY, To K, Wong VWS. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B: Steatosis and cancer in hepatitis B. Journal of Gastroenterology and Hepatology 2017;32:667-76. [DOI: 10.1111/jgh.13536] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 15.8] [Reference Citation Analysis]
29 Liang X, Wu K, Liu M, Yang B. Adverse impact of carbon tetrachloride on metabolic function in mice. J Cell Biochem 2019. [PMID: 30775809 DOI: 10.1002/jcb.28481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Amponsah-Dacosta E, Tamandjou Tchuem C, Anderson M. Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome. World J Virol 2020; 9(5): 54-66 [PMID: 33362998 DOI: 10.5501/wjv.v9.i5.54] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Yen FS, Lai JN, Wei JC, Chiu LT, Hsu CC, Hou MC, Hwu CM. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis? BMC Gastroenterol 2021;21:263. [PMID: 34118892 DOI: 10.1186/s12876-021-01773-x] [Reference Citation Analysis]
32 Xu C, Chen J, Zhang PA. Relationship Between Diabetes Mellitus and Cirrhosis Risk in Chronic Hepatitis B Patients in Wuhan, China. Med Sci Monit. 2019;25:8112-8119. [PMID: 31661471 DOI: 10.12659/msm.917000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Luo D, Dong X, Huang J, Huang C, Fang G, Huang Y. Pueraria lobata root polysaccharide alleviates glucose and lipid metabolic dysfunction in diabetic db/db mice. Pharm Biol 2021;59:382-90. [PMID: 33794128 DOI: 10.1080/13880209.2021.1898648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tang C, Hu C, Zhou Y, Song Y, Li M, Liao M, Sun J, Zhong C, Zhou L, Lin Z, Zhou Y. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study]. Nan Fang Yi Ke Da Xue Xue Bao 2021;41:313-8. [PMID: 33849820 DOI: 10.12122/j.issn.1673-4254.2021.03.01] [Reference Citation Analysis]
35 Sharkawi SMZ, El-Shoura EAM, Abo-Youssef AM, Hemeida RAM. The potential hepatoprotective effects of lovastatin combined with oral hypoglycemic agents in streptozotocin-induced diabetes in rats. Immunopharmacol Immunotoxicol 2020;42:165-73. [PMID: 32114843 DOI: 10.1080/08923973.2020.1733013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhao Y, Xing H, Wang X, Ou W, Zhao H, Li B, Li Y, Duan Y, Zhuang L, Li W, Cheng D, Quan M, Zhang Y, Ji S. Management of Diabetes Mellitus in Patients with Chronic Liver Diseases. J Diabetes Res 2019;2019:6430486. [PMID: 31915709 DOI: 10.1155/2019/6430486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Sreedhar H, Varma VK, Gambacorta FV, Guzman G, Walsh MJ. Infrared spectroscopic imaging detects chemical modifications in liver fibrosis due to diabetes and disease. Biomed Opt Express 2016;7:2419-24. [PMID: 27375956 DOI: 10.1364/BOE.7.002419] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
38 Tan Y, Wei S, Zhang W, Yang J, Yang J, Yan L. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res 2019;11:705-13. [PMID: 30679924 DOI: 10.2147/CMAR.S188238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
39 Chen CY, Lin CJ, Lin CS, Sun FJ, Pan CF, Chen HH, Wu CJ. The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation. Oncotarget. 2018;9:2236-2248. [PMID: 29416767 DOI: 10.18632/oncotarget.23368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]